Insulet Corporation and Bigfoot Biomedical have announced that Insulet has acquired assets related to Bigfoot’s pump-based automated insulin delivery (AID) technologies.
The transaction further strengthens Insulet’s intellectual property (IP) portfolio and provides Bigfoot with additional capital to expand its Bigfoot Unity Diabetes Management System to more people in need of connected insulin injection support technologies.
Said Eric Benjamin, Insulet’s Executive Vice President of Innovation, Strategy, and Digital Products, “Bigfoot has made valuable contributions to the industry through many years of research and development in these fields and we are thrilled to acquire these assets. Insulet has substantially strengthened its IP portfolio organically over the past few years. And with this acquisition, we approximately double our already strong IP portfolio.”
To read more, CLICK HERE
